ALNY Company Profile and Key Details

Q: Who are the executives of ALNY?

Mr. Mark BaglinVice President of Global MarketingMr. Piyush Sharma J.D.Chief Ethics & Compliance OfficerMr. Michael W. Bonney B.A.Executive ChairmanDr. Akshay K. Vaishnaw M.D., Ph.D.PresMr. Tolga Tanguler M.B.A.Executive Vice President & Chief Commercial OfficerDr. Alfred W. Boyle Ph.D.Chief Technical Operations & Quality OfficerMr. Timothy J. MainesChief Technical Operations & Quality OfficerMs. Christine Regan LindenboomSenior Vice President of Investor Relations & Corporation CommunicationsDr. Yvonne L. Greenstreet M.B.A., MBA, MBChBChief Executive Officer & DirectorMs. Indrani M. Lall Franchini J.D.Executive Vice President, Chief Legal Officer & Sec.Mr. Jeffrey V. Poulton M.B.A.Chief Financial Officer & Executive Vice PresidentDr. Pushkal P. Garg M.D.Chief Medical Officer and Executive Vice President of Devel. & Medical AffairsDr. Kevin Joseph Fitzgerald Ph.D.Senior Vice President, Head of Research & Chief Scientific Officer

NASDAQ : ALNY

Alnylam Pharmaceuticals

$331.24

-20.72-5.89%

At Close 4:00 PM

61.45

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Alnylam Pharmaceuticals, Inc. (ALNY) stock declined over -5.89%, trading at $331.24 on NASDAQ, down from the previous close of $351.96. The stock opened at $349.62, fluctuating between $327.27 and $350.36 in the recent session.

Stock Snapshot

351.96

Prev. Close

43.76B

Market Cap

327.27

Day Low

1035.13

P/E Ratio

0.32

EPS (TTM)

0.33

Cash Flow per Share

349.62

Open

132.11M

Number of Shares

350.36

Day High

96.24%

Free Float in %

-1.76

Book Value

2.6M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 05, 2026	350.50	350.50	327.27	331.24	2.62M
Feb 04, 2026	354.00	355.49	347.08	351.96	1.78M
Feb 03, 2026	338.49	352.82	337.59	351.80	2.15M
Feb 02, 2026	337.42	342.33	333.00	339.11	1.91M
Jan 30, 2026	343.10	346.50	336.39	338.06	1.65M
Jan 29, 2026	349.37	350.34	345.01	346.79	1.63M
Jan 28, 2026	353.66	356.84	348.00	349.58	1.06M
Jan 27, 2026	361.55	368.07	354.69	354.75	986.59K
Jan 26, 2026	357.98	364.07	352.50	361.35	935.12K
Jan 23, 2026	368.20	371.33	356.72	357.98	1.63M
Jan 22, 2026	365.50	376.87	363.36	370.00	1.86M
Jan 21, 2026	353.01	366.00	351.55	365.46	1.52M
Jan 20, 2026	350.70	355.74	347.77	355.53	1.72M
Jan 16, 2026	362.29	367.20	355.46	359.27	1.52M
Jan 15, 2026	368.54	372.82	356.83	359.26	889.88K
Jan 14, 2026	369.95	371.71	359.95	366.86	1.2M
Jan 13, 2026	369.10	376.88	366.92	369.96	1.62M
Jan 12, 2026	377.82	378.61	353.52	370.91	3.81M
Jan 09, 2026	399.40	409.58	392.56	398.29	1.43M
Jan 08, 2026	420.18	425.19	393.48	399.40	1.4M

Contact Details

Cambridge, MA 02142

United States

https://www.alnylam.com 617 551 8200

About Company

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Stock Peers

ARGX

-30.56-3.59%

argenx SE$820.31 REGN

-8.645-1.12%

Regeneron Pharmaceuticals, Inc.$766.63 UTHR

-3.66-0.76%

United Therapeutics Corporation$478.93 MDGL

-15.19-3.17%

Madrigal Pharmaceuticals, Inc.$463.42 VRTX

-11.71-2.49%

Vertex Pharmaceuticals Incorporated$458.81 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

2.28+0.75%

Praxis Precision Medicines, Inc.$305.62 KRYS

-1.49-0.55%

Krystal Biotech, Inc.$267.64 SGEN

-0.16-0.07%

Seagen Inc.$228.74 CDTX

Cidara Therapeutics, Inc.$221.38

Company Overview

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) closed at $331.24 USD, losing -$20.72 (-5.89%) from the previous close of $351.96. The stock is currently mid-range between its 52-week high and low $205.87 and $495.55. With a market capitalization of about $43.76 billion, Alnylam Pharmaceuticals, Inc. is classified as a large-cap and shows lower-than-market volatility (beta ~0.35). Key stats such as the average daily volume over the past year has been around 1.43 million shares, trading with heavier-than-usual volume. Headquartered in Cambridge, MA, Alnylam Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Yvonne L. Greenstreet, the company employs approximately 2,230 people and listed since June 01, 2004. Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.

Technical Performance

ALNY has shown weak momentum, losing -4.15% over the past week and -26.19% over the past quarter, though year-to-date performance is down -10.59%. Short-term trend indicators are mixed aligned (SMA20 -7.96%, SMA50 -16.07%, SMA200 -13.98%). The stock’s 14-day RSI is 30.75 (weak momentum), while the ATR of 14.03 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -33.16% below its high and over 60.9% above its low. Average 10-day trading volume of 1.72 million shares is slightly above the 3-month average of 1.39 million, indicating heightened recent market interest.

Valuation Metrics

Alnylam Pharmaceuticals, Inc. trades at a P/E ratio of 1000.86, slightly above the S&P 500 average, with a price-to-sales ratio of 13.65 and a price-to-book ratio of 186.42 reflecting a rich premium to book value. The P/FCF stands at 197.97, also above market averages. Compared to sector medians, Alnylam Pharmaceuticals, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Alnylam Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $213.78. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Alnylam Pharmaceuticals, Inc. generated EPS of $0.24 over the past year. Five-year average earnings growth is 23.11%. The latest quarter delivered EPS of $1.84. The next quarter is forecast at $1.16. Next year's EPS is expected at -$21.13. Analyst sentiment is bullish. Analyst rating data shows there are 23 Strong Buy ratings, 40 Buy ratings, 11 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $583.00 to $280.00. The high target offers 76.01% upside. The low target suggests -15.47% downside. The mean target is $424.64. This offers 28.2% upside. Alnylam Pharmaceuticals, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended October 30, 2025, missed forecasts by 227.99%. The prior quarter beat by -158.85%. Over the last six quarters, Apple has recorded several small beats. These include -87.85% in August 01, 2024.

Shareholding & Insider Activity

Alnylam Pharmaceuticals, Inc. has 132.11 million shares outstanding. The public float is 130.23 million shares, elevated short interest at 5.54% of float. This equals 5.57 million shares. The short ratio is 3.22 days. Institutional investors hold 101.74% of the float. Insiders own 1.47%. Greenstreet Yvonne holds 78.41 thousand shares, Poulton Jeffrey V. has 57.46 thousand shares and Tanguler Tolga has 29.73 thousand shares. Over the past six months, insider transactions show net selling. They sold 14.06 thousand shares across 25 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Alnylam Pharmaceuticals generated $1.83B in revenue, or $14.64 per share. Gross margin was 83.02%, operating margin -15.43%, and net profit margin -24.08%. Returns are negative, with ROA at -11.49% and ROE at 199.53%.
On valuation metrics, Alnylam Pharmaceuticals trades at a P/E of 1000.86, P/S of 13.65 and P/B of 186.42. The current ratio is 2.54 and quick ratio is 2.49. Operationally, the company’s inventory turnover is 6.82 and cash conversion cycle is 79.73 days. Debt-to-equity is 11.86, supported by a cash flow-to-debt ratio of 0.10.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Alnylam Pharmaceuticals posted revenue of $1.83B, down slightly from $1.04B in the prior quarter. Gross profit was $1.52B (margin 83.02%). Operating income was - $282.18M (margin -15.4%). Net income was- $440.24M (EPS - $3.52).
The company ended the quarter with $2.44B in cash and short-term investments, a total debt of $2.68B, and net debt of $1.87B. Total assets were $3.83B, with equity of - $220.64M. Financials further reflected stability, with operating cash flow of $104.16M, free cash flow of $41.95M, and capital expenditures of - $62.21M.

Price Forecast & Outlook

Our AI price prediction model suggests that Alnylam Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -6.55%, with price expected at $309.56 by February 19, 2026, within a range of $297.64 to $322.39 3-Month Outlook: Projected fall of -45.5%, reaching $180.53 by May 06, 2026, with a range of $170.81 to $187.92. 1-Year Outlook: Projected gain of 29.28%, with price at $428.23 by February 05, 2027, within a range of $403.12 to $449.37.

Key Takeaways

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares are down -10.59% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Alnylam Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of 1000.86. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $328.65, suggesting -0.78% downside. Our AI forecast model points to short-term weakness (-6.55% over two weeks), a medium-term fall (-45.5% over three months), and a longer-term gain (29.28% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Alnylam Pharmaceuticals, Inc. (ALNY) stock price?

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) stock price is $331.24 in the last trading session. During the trading session, ALNY stock reached the peak price of $350.36 while $327.27 was the lowest point it dropped to. The percentage change in ALNY stock occurred in the recent session was -5.89% while the dollar amount for the price change in ALNY stock was - $20.72.

ALNY's industry and sector of operation?

The NASDAQ listed ALNY is part of Biotechnology industry that operates in the broader Healthcare sector. Alnylam Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ALNY?

Mr. Mark Baglin
Vice President of Global Marketing
Mr. Piyush Sharma J.D.
Chief Ethics & Compliance Officer
Mr. Michael W. Bonney B.A.
Executive Chairman
Dr. Akshay K. Vaishnaw M.D., Ph.D.
Pres
Mr. Tolga Tanguler M.B.A.
Executive Vice President & Chief Commercial Officer
Dr. Alfred W. Boyle Ph.D.
Chief Technical Operations & Quality Officer
Mr. Timothy J. Maines
Chief Technical Operations & Quality Officer
Ms. Christine Regan Lindenboom
Senior Vice President of Investor Relations & Corporation Communications
Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB
Chief Executive Officer & Director
Ms. Indrani M. Lall Franchini J.D.
Executive Vice President, Chief Legal Officer & Sec.
Mr. Jeffrey V. Poulton M.B.A.
Chief Financial Officer & Executive Vice President
Dr. Pushkal P. Garg M.D.
Chief Medical Officer and Executive Vice President of Devel. & Medical Affairs
Dr. Kevin Joseph Fitzgerald Ph.D.
Senior Vice President, Head of Research & Chief Scientific Officer

How ALNY did perform over past 52-week?

ALNY's closing price is 60.9% higher than its 52-week low of $205.87 where as its distance from 52-week high of $495.55 is -33.16%.

How many employees does ALNY have?

Number of ALNY employees currently stands at 2,230.

Link for ALNY official website?

Official Website of ALNY is: https://www.alnylam.com

How do I contact ALNY?

ALNY could be contacted at phone 617 551 8200 and can also be accessed through its website. ALNY operates from 675 West Kendall Street, Cambridge, MA 02142, United States.

How many shares of ALNY are traded daily?

ALNY stock volume for the day was 2.6M shares. The average number of ALNY shares traded daily for last 3 months was 1.43M.

What is the market cap of ALNY currently?

The market value of ALNY currently stands at $43.76B with its latest stock price at $331.24 and 132.11M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	2230
Beta	0.32
Sales or Revenue	$1.83B
5Y Sales Change%	18.656%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

ALNY Company Profile and Key Details

Alnylam Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Company Overview

Valuation Metrics

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Price Forecast & Outlook

Key Takeaways